Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 922) were randomized to receive 10 mg dapagliflozin or placebo in a double-blind trial for 24 weeks, followed by a 28-week extension period. In patients receiving insulin, the insulin dose was reduced by 25% at randomization. Patients were stratified by age, insulin use, and time from the most recent qualifying cardiovascular (CV) event. Co-primary end points were a change from baseline in hemoglobin A1c (HbA1c) and the proportion of patients achieving a combined reduction in HbA1c of ≥0.5% (5.5 mmol/mol), body weight (BW) of ≥3%, and systolic blood pressure (SBP) of ≥3 mmHg. RESULTS: At 24 weeks, dapagliflozin significantly reduced HbA1c (−0.38% [−4.2 mmol/mol]) from baseline (8.18%) compared with a slight increase with placebo from baseline (8.08%) (0.08% [0.9 mmol/mol]). Significantly more patients met the three-item end point with treatment with dapagliflozin than with placebo (11.7% vs. 0.9%, respectively). Changes were maintained over 52 weeks. Although ∼42% of patients were ≥65 years old, similar results were observed in both age-stratified groups. Serious adverse events, hypoglycemia, urinary tract infections, and cardiac disorders were similar between groups. Adverse events of hypotension, dehydration, hypovolemia, genital infection, and renal failure or impairment occurred more often with dapagliflozin treatment. CONCLUSIONS: In this study that evaluated T2D patients who were at high risk for future CVD events, dapagliflozin administration had significantly greater effects in reducing HbA1c, BW, and SBP, without adversely impacting CV safety when compared with placebo treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The addition of metabolic surgery (148), weight loss medications (149), and glucose-lowering agents that promote weight loss (150) can also be used as an adjunct to lifestyle interventions, resulting in greater weight loss that is maintained for a longer period of time.”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 101–181 of 181
Fioretto, P., & Avogaro, A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1300253 · Cited by 13
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
Armour, S. L., Frueh, A., & Knudsen, J. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837664 · Cited by 13
Mende, C. W., & Katz, A. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0158-y · Cited by 11
“gov identifier, NCT00528372) [19]; as initial combination therapy with metformin (NCT00859898) [20]; and as add-on to the following: metformin (NCT00528879 and NCT00855166) [21, 22], glimepiride (NCT00680745) [23], sitagliptin ±metformin (NCT00984867) [24], insulin ± up to 2 other antidiabetes medications (NCT00673231…”
BackgroundZhang, X., Zhong, Z., Li, Y., & Li, W. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3303 · Cited by 11
“Of these, three trials contained groups on three different doses of SGLT2 inhibitors,(9,10,42) 20 trials contained groups on two different doses of SGLT2 inhibitors(12,14,15,19,21,23,25-27,29,30,36-39,44-46) and 12 trials contained only one group on SGLT2 inhibitors.(13,14,17,18,20,23,24,28,31-35,40,43) One trial cont…”
BackgroundIdzerda, N. M. A., Stefánsson, B. V., Pena, M. J., Sjöström, C. D., Wheeler, D. C., & Heerspink, H. J. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz064 · Cited by 14
Obaid, M. I., Shahzad, M. S., Latif, F., Khan, M. H., Akram, M., Rizvi, S. A. M., Nasrullah, R. M. U., Asad, D., & Obaid, M. A. (2024) · Future Science OA · doi:10.1080/20565623.2024.2400797 · Cited by 11
Nashar, K., & Khalil, P. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s234282 · Cited by 14
“The glucose-lowering effect of dapagliflozin was similar in patients with or without cardiovascular disease and hypertension.(20,21) In a pooled analysis of five, Phase 2–3 clinical trials of ≤52 weeks’ duration, patients with T2D and a history of heart failure saw an improvement in glycated hemoglobin from baseline (…”
BackgroundDapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C
SKOLNIK, N., Bonnes, H., Yeh, H., & Katz, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1173514 · Cited by 12
“5 53 5 10 NCT 01031680 [33] CV risk, add-on to usual care 922 7.”
BackgroundInfluentialYang, S., He, W., Zhao, L., & Mi, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267025 · Cited by 10
“The heterogeneity was reduced when we excluded one large study [18] and an outlying study [19] (I(2) = 39.”
BackgroundKabadi, U. M. (2015) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2015.54026 · Cited by 9
“Unfortunately though, lack of increase or decrease in cardiovascular outcomes has become the standard of cardiovascular safety as documented in recent trials with newer agents [15] [16] [76]-[84] rather than lowering of these outcomes with improvement in glycemic control as was documented in UKPDS and Advance studies…”
ResultMerton, K., Davies, M. J., Vijapurkar, U., Inman, D., & Meininger, G. E. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1391759 · Cited by 10
“5% (generally acceptable threshold for regulatory approval), body weight reduction ≥3% (clinically significant threshold used in a previous analysis of an SGLT2 inhibitor [32]), and systolic BP reduction ≥4 mmHg (associated with CV benefits [12]), as well as the proportion of patients achieving the composite of the 3…”
BackgroundHsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Jiang, L., Zhang, P., Liu, B., Yan, R., Ye, L., Ma, J., & Li, F.-F. (2021) · BioMed Research International · doi:10.1155/2021/6618257 · Cited by 9
Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
Li, P., Chen, W., Chen, R., Zhang, H., Yu, Z., Yan, H., Du, B., & Yang, P. C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558367 · Cited by 8
Wang, Y., & Zhou, X. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03631-7 · Cited by 7
Jiang, M., Liu, Q., Jiang, T., Nizigiyimana, P., & Lei, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.713192 · Cited by 10
Galli, M., D’Amario, D., Sofia, C., Vaccarella, M., Crea, F., & Aspromonte, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551360 · Cited by 8
“Patients treated with empagliflozin commonly suffer from headaches [7,46].”
BackgroundA review of cardiovascular benefits of SGLT2 inhibitors
Zhang, Y., & Han, Q. (2022) · Medicine · doi:10.1097/md.0000000000030310 · Cited by 9
“[7] As more in-depth studies have been conducted, its cardiovascular protection effects have been confirmed.”
BackgroundZiser, K. E. D., Livori, A., Morton, J. I., Prosser, A. E., Ilomäki, J., & Wood, S. J. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16088 · Cited by 8
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Wong, H. J., Lin, N., Teo, Y. N., Syn, N. L. X., Teo, Y. H., & Sia, C. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00640-w · Cited by 7
“Exceptions included Cefalu et al. [24], raising minor concerns under Domain 5 of the RoB for RCTs, and Retwiński et al. [25], which achieved 6 of 9 points after completing the NOS.”
Abouzaid, H. H., El-Yamany, M. F., Mosaad, Y. O., Sayed‐Ahmed, M. M., Karkeet, R. M., & El-Sahar, A. E. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01681-z · Cited by 5
“DAPA reported side effects are increased risk of genital as well as urinary tract infections, hypotension, dehydration and diabetic ketoaci - dosis (Cefalu et al. 2015; Pelletier et al. 2021).”
Balleza-Alejandri, L. R., Páez, F. G., Campos, E. G., Becerra, C. G. R., Muñoz, E., González, S. P., Ramos-Zavala, M. G., Reynoso-Roa, A. S., Suárez-Rico, D. O., Beltrán-Ramírez, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11060182 · Cited by 8
“SGLT2 inhibitors (SGLT-2i) have been shown to decrease cardiovascular risk in patients with type 2 diabetes mellitus, decreasing arterial stiffness as well as endothelial dysfunction compared to a placebo and other agents [12–15].”
BackgroundBhagya, G., Namini, M. T., Girish, B. S., & Srinivasan, R. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.274 · Cited by 6
“The overall reduction in SBP ranged from 2.3 to 7.2 mmHg, while reductions in DBP ranged from 1.0 to 2.8 mmHg [38].”
InfluentialIntensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Han, Y., Li, Y., Ye, C.-W., Gu, Y.-Y., Chen, X., Gu, Q., Xu, Q.-Q., Wang, X.-M., He, S., & Wang, D. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12461 · Cited by 4
Huang, L., Hu, R., & Zou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419729 · Cited by 4
Dapagliflozin combination therapy in type 2 diabetes mellitus
Yacoub, T. G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1111119 · Cited by 6
Kumar, S., Talwalkar, P., Das, S., & Goswami, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_161_17 · Cited by 3
Zhang, Q., Zhang, Q., Liu, Y., Yang, S., & Yu, L. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03719-6 · Cited by 4
Tang, Y., Zhang, Y., Liu, X., Chen, G., Yin, L., & Wu, M. (2026) · Journal of International Medical Research · doi:10.1177/03000605261421036 · Cited by 2
Jiang, L., Jia, Y., Wang, X., Wang, Z., Lv, X., Jia, Y., Feng, Y., Yin, H., Yan, M., Fan, X., et al. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2166485 · Cited by 2
“One possible explanation for this may be due to mechanism-related hemodynamic changes resulting from the mild osmotic diuretic effect or other multiple concomitant medications effects, since the patients and participants of the present study aged 60 and older are living longer with T2DM and have multiple comorbid cond…”
BackgroundIn Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
Debnath, A., Sharma, S., Mazumder, R., Mazumder, A., Singh, R. K., Kumar, A., Dua, A., Singhal, P., Kumar, A., & Singh, G. (2023) · Current Drug Discovery Technologies · doi:10.2174/0115701638267615231123160650 · Cited by 3
Akkuş, O., Akkuş, G., & Kaypaklı, O. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666181218121508 · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
“Since SGLT2i act strictly glucose-dependently, they do not increase the likelihood of hypoglycemia, even in combination with insulin [203,207].”
BackgroundAspects of the safety of hypoglycemic drugs according to the results of clinical trials
Хохлов, А. Л., Горелов, К. В., & Rybachkova, J. V. (2023) · Patient-Oriented Medicine and Pharmacy · doi:10.37489/2949-1924-0016 · Cited by 2
Hu, X., Tan, C., Liu, X., Zhang, N., Wang, F., & Wang, Z. (2024) · Kardiologiia · doi:10.18087/cardio.2024.12.n2701 · Cited by 1
Lora-Escobar, S. J., Francisco, L. R.-D., López-Feijoo, M., Santos‐Ramos, B., Bellido, V., Mejía, R. M. C., & Acosta-García, H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3733178 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Yu, Z., Gu, B., Zhang, J., Jin, W., Wan, H., & Jin, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1721311 · Cited by 3
Omrani, M. A., Baskaran, B. S., Sadeghi, H., Ahmadi, F., Eddin, L. E., Jafari, A., & Muanda, F. T. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2641874 · Cited by 2
Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Steinberg, H. O. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1168687 · Cited by 2
“Hypertension is a common comorbid condition of T2DM,[1] and is associated with an increased risk of CVD.[82] Some, but not all, glucose-lowering agents have been shown to exert BP-lowering effects (e.g. DPP-4 inhibitors,[83] GLP-1 agonists,[84,85] and TZD [86]); however, these effects were generally small and no signi…”
InfluentialMeta-Analysis on Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus
She, L., & Wu, H. (2018) · Yangtze Medicine · doi:10.4236/ym.2018.23014 · Cited by 1
“A total of 13 studies were implemented [3] [9] [10] [12] [13] [15]-[20] [22] [23] to compare renal adverse events.”
BackgroundManjula, S., & Krishna Kumar, M. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_32_24 · Cited by 1
İsmayılova, S., Məmmədzadə, A. Y., Muradova, S. R., Huseynova, N. I., Məmmədova, A. P., Kazimli, A. V. K., & Huseyn, L. A. (2025) · Azerbajdžanskij medicinskij žurnal · doi:10.34921/amj.2025.1.006 · Cited by 1
The impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus
Stelmaszyk, A., & Dworacka, M. (2017) · Clinical Diabetology · doi:10.5603/dk.2017.0024 · Cited by 1
Sukkar, L., Young, T. K., & Jardine, M. (2020) · Kidney & Blood Pressure Research · doi:10.1159/000511214 · Cited by 2
Septic Shock Due to Urinary Tract Infection in an Immunosuppressed Patient Prescribed Dapagliflozin
Suetani, Y., Arita, Y., Iida, Y., & Ogasawara, N. (2022) · Cureus · doi:10.7759/cureus.30552 · Cited by 3
“When prescribing SGLT2 inhibitors to patients, clinicians should always consider the possibility of UTIs and cases in which the drugs should be used.”
BackgroundInfluentialJha, S. K., Singh, N. K., & Mahajan, A. (2020) · doi:10.9734/ajrre/2020/v3i111
Rieth, A. J., Hamm, C. W., Wanner, C., Mitrović, V. L., & Keller, T. (2020) · Herz · doi:10.1007/s00059-020-04994-0
Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
Dekkers, C. C. J. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.136049658
Strategies for the Management of Type 2 Diabetes
Winocour, P. H., & Zac‐Varghese, S. (2022) · doi:10.1093/med/9780198870197.003.0259
Zheng, Z., He, D., Chen, J., Xie, X., Lu, Y., Wu, B., & Jiang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1850015/v1
Efficacy and Safety of Dapagliflozin: Report from A Tertiary Care Hospital of Karnataka
Vishwas, M. K., Phaneshwara, B. N., Raghvendra, P. V. U., & Vasudha, K. (2022) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2022.v75i02.005
“For the purpose of the study, inclusion criteria were: diagnosed cases of T2DM and those patients who were on metformin with or without another insulin lowering agent.”
BackgroundInfluentialReview on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus
Mukhopadhyay, J. (2022) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2022.20.3.0371
“Incidences of genital mycotic infections, urinary tract infections, and osmotic diuresis–related adverse events were higher in clinical trials but were generally mild to moderate in intensity and led to few discontinuations (67, 68).”
BackgroundA Review on The Use of Dapagliflozin in Cardiovascular Diseases
Satish, S., Shifnaz, N. P., & Shabaraya, A. R. (2023) · International Journal of Research and Review · doi:10.52403/ijrr.20230106
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Paccone, A., Maurea, C., Scherillo, M., Merola, A., Giordano, V., Palma, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3159387/v1
Cai, Y., Zou, H., Hu, R., Chen, H., Yang, G., & Gong, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376446
Prevalence of genitourinary symptoms in people with type 2 diabetes initiated with SGLT2 inhibitors
Viswanathan, V., Samraj, D., Baid, L., & Kumpatla, S. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01364-y
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Kempf, K., Röhling, M., & Martin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1644442 · Cited by 1
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574907
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574919
Li, H., Lip, G. Y. H., Feng, Q., Fei, Y., Tse, Y.-K., Wu, M.-Z., Ren, Q.-W., Tse, H., Cheung, B.-M. Y., & Yiu, K.-H. (2021) · Figshare · doi:10.6084/m9.figshare.14559209
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574922
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574910
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C.-H., Chen, C.-H., & Yeh, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26574913
Jaiswal, V., Mashkoor, Y., Waqas, M., Khan, M. S., Ahmed, A. B., Deb, N., Banach, M., Dani, S. S., Zelniker, T. A., Alexander, K. M., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.024
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Teng, J., Li, T., Tan, Y., & Tang, H. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1775359
“Additionally, the sample size in Cefalu2015 was insuf fi cient to draw conclusions regarding rare events (52, 82).”
Gao, S., Zhang, F., Xie, X., & Fan, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1843370 · Cited by 1
Sagan, D., Góral, M., Siedlecki, R., Fidorowicz, D., Sergiel, K. H., Torbacka, E., Skuza, A. I., Downar-Zapolska, M., Mikłaszewicz, A., & Bednarczuk, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5476
Alyas, J. T., Nielsen, S. F., & Buus, N. H. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004386
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Huang, T., Yap, L., Lin, H., Su, P., Liao, Y., Chen, C., Lee, P., Lin, S., & Li, Y. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049649
Efficacy and mechanistic insights of dapagliflozin in hypertension management
Chen, Z., Chunbin, W., Zhang, H., Luo, T., & Yan, J. (2026) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2026.2731624
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Metadata
- Authors
- Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J.
- Affiliations
- Pennington Biomedical Research Center (US)
- St. Michael's Hospital (CA)
- AstraZeneca, Global Medicines Development, Gaithersburg, MD
- AstraZeneca, Global Medicines Development, Mölndal, Sweden
- AstraZeneca (United States) (US)
- Corresponding author
- Cefalu, William T.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-07
- Volume
- 38
- Issue
- 7
- Pages
- 1218-1227
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4831907
- OpenAlex
- W2076506641
- Cited by
- 182
- References
- 29
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 24 · 2023: 12 · 2022: 15 · 2021: 20 · 2020: 10 · 2019: 16 · 2018: 14 · 2017: 17 · 2016: 20 · 2015: 5
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Intarcia Therapeutics
- MannKind Corporation
- Halozyme
- Novo Nordisk
- Servier
- National Institutes of Health
- National Institute of General Medical Sciences (104940, GM104940, U54GM104940)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, cardiovascular risk, hypertension, HbA1c, weight loss, systolic blood pressure, insulin dose reduction, adverse events, renal failure, urinary tract infection, older adults, cardiovascular safety, high-risk patients, hypoglycemia
- MeSH terms
- Analysis of Variance, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Urinary Tract Infections, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.